Search
KP-1461
go.drugbank.com/drugs/DB05644InvestigationalKP-1461 is a potent, non-chain-terminating, mutagenic deoxyribonucleoside analogue. Designated a DNA covert nucleoside, the drug consists of a modified base that incorporates randomly into HIV and pairs with multiple bases.
Necuparanib
go.drugbank.com/drugs/DB16251InvestigationalNecuparanib is under investigation in clinical trial NCT01621243 (M402 in Combination With Nab-paclitaxel and Gemcitabine in Pancreatic Cancer).
ABX-196
go.drugbank.com/drugs/DB16339InvestigationalABX-196 is under investigation in clinical trial NCT03897543 (ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma).
Tersolisib
go.drugbank.com/drugs/DB21752InvestigationalSTX-478 is under investigation in clinical trail NCT05768139 (First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Stepronin
go.drugbank.com/drugs/DB01423ExperimentalThe viscosity of mucous secretions in the lungs is dependent upon the concentrations of mucoprotein as well as the presence of disulfide bonds between these macromolecules and DNA.
Eptifibatide
go.drugbank.com/drugs/DB00063ApprovedInvestigationalSynthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation. Derived from venom of the Southeastern pygmy rattlesnake (Sistrurus miliarus barbouri), eptifibatide is a cyclic heptapeptide th...
Nedisertib
go.drugbank.com/drugs/DB16252InvestigationalNedisertib is under investigation in clinical trial NCT03770689 (Study of M3814 in Combination With Capecitabine and Radiotherapy in Rectal Cancer).
Rupitasertib
go.drugbank.com/drugs/DB15431InvestigationalM-2698 is under investigation in clinical trial NCT01971515 (First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies).
XAV-19
go.drugbank.com/drugs/DB15895InvestigationalXAV-19 is an intravenous antibody-based treatment targeted towards SARS-CoV-2 and other coronaviruses[L16553,L16558]. The therapy concept is based on [COVID-19 convalescent plasma]. … Xenothera has partnered with LFB, a pharmaceutical company, to develop XAV-19, and with Nantes University Hospital to test the treatment in patients[L16553,L16558].